Safety and efficacy of adjuvant subcutaneous trastuzumab in human epidermal growth factor receptor 2-positive early breast cancer: Final results of the SafeHER study.

Date publication

mars 2022

Journal

Breast (Edinburgh, Scotland)

Auteurs

Membres identifiés du Cancéropôle Est :
Pr PIVOT Xavier

Tous les auteurs :
Gligorov J, Pivot X, Ataseven B, De Laurentiis M, Jung KH, Manikhas A, Abdel Azim H, Gupta K, Alexandrou A, Herraez-Baranda L, Tosti N, Restuccia E

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/35487845

Résumé

To report the final results of the 5-year follow-up of the non-randomized SafeHER Phase III study (NCT01566721) describing the safety, tolerability, and efficacy of subcutaneous (SC) trastuzumab alone and in combination with concurrent or sequential chemotherapy.

Mots clés

Breast neoplasms, Disease-free survival, Follow-up studies, Receptor ErbB2, Safety, Trastuzumab

Référence

Breast. 2022 Mar 17;: